Literature DB >> 26447897

Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.

Patricia L Kandalaft1, Rochelle A Simon, Christina Isacson, Allen M Gown.   

Abstract

GATA-3 is a transcription factor that has recently been identified by immunohistochemistry to be highly expressed in urothelial and breast carcinomas (CAs). We sought to determine the potential utility of GATA-3 in identifying metastatic breast CA, and to compare its utility with the standard breast markers, GCDFP-15, and mammaglobin A. We identified an archival series of 338 formalin-fixed paraffin-embedded whole-tissue sections of various CAs. Using standard immunohistochemical (IHC) techniques we used mouse monoclonal antibodies to GATA-3 (clones L50-823, HG3-31), GCDFP-15 (23A3), and mammaglobin A (31A5). Both clones of GATA-3 showed positivity in 96% of non-triple-negative breast carcinomas (TNBCs), L50-823 and HG3-31, demonstrating expression in 87% and 63% of TNBCs, respectively; GCDFP-15 and mammaglobin A were expressed in 69% and 61% of non-TNBCs, respectively, and 10% and 17%, of TNBCs, respectively. The L50-823 clone manifested a lower specificity in identifying breast CAs (84%) than did the HG3-31 clone (97%). Both monoclonal antibodies to GATA-3 are very sensitive reagents for the identification of breast CA, surpassing antibodies to GCDFP-15 and mammaglobin A, and offer a significant improvement in identifying TNBCs. However, the L50-823 clone showed a lower level of specificity, which may qualify its utility in the setting of CAs of unknown primary.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26447897     DOI: 10.1097/PAI.0000000000000237

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

Review 1.  The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.

Authors:  Ankur R Sangoi; Bijayee Shrestha; George Yang; Ourhay Mego; Andrew H Beck
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-04

Review 2.  Case Report and Review of Literature: Thyroid Metastases From Breast Carcinoma.

Authors:  Yichao Wang; Shengliang Zhou; Boyang Yu; Ping Zhou; Jingqiang Zhu; Tao Wei; Zhihui Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

Review 3.  Cancer of Unknown Primary: Challenges and Progress in Clinical Management.

Authors:  Noemi Laprovitera; Mattia Riefolo; Elisa Ambrosini; Christiane Klec; Martin Pichler; Manuela Ferracin
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

4.  Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance.

Authors:  Xin Kong; Qi Wang; Jie Li; Ming Li; Fusheng Deng; Chuanying Li
Journal:  Eur J Histochem       Date:  2022-04-07       Impact factor: 1.966

Review 5.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

6.  Preferential expression of NY-BR-1 and GATA-3 in male breast cancer.

Authors:  Giovanni Battista Biserni; Enrico Di Oto; Linda Eszter Moskovszky; Maria Pia Foschini; Zsuzsanna Varga
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-07       Impact factor: 4.553

7.  Metastatic adenocarcinoma to the breast from the lung simulates primary breast carcinoma-a clinicopathologic study.

Authors:  Xin Wang; Yang Luo; Li Liu; Jiacong Wei; Huizi Lei; Susheng Shi; Lin Yang
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

8.  Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.

Authors:  Carina Bernardo; Fátima L Monteiro; Inês Direito; Francisco Amado; Vera Afreixo; Lúcio L Santos; Luisa A Helguero
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.